Stryker (SYK) Hisse Özeti
Stryker Corporation, Amerika Birleşik Devletleri'nde ve uluslararası alanda bir tıbbi teknoloji şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 5/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 4/6 |
SYK Community Fair Values
Create NarrativeSee what 111 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$323.52
FV
1.8% aşırı değerlenmiş içsel indirim6.00%
Revenue growth p.a.
432
users have viewed this narrative5users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
Stryker Corporation Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$329.45 |
| 52 Haftanın En Yüksek Seviyesi | US$396.86 |
| 52 Haftanın En Düşük Seviyesi | US$281.00 |
| Beta | 0.77 |
| 1 Aylık Değişim | -0.24% |
| 3 Aylık Değişim | 5.26% |
| 1 Yıllık Değişim | -15.72% |
| 3 Yıllık Değişim | 18.38% |
| 5 Yıllık Değişim | 20.20% |
| Halka arzdan bu yana değişim | 60,721.50% |
Son Haberler & Güncellemeler
Recent updates
Seeking Alpha • Aug 18
Stryker Corporation: Hold For Quality, Wait For The Dip
Summary Stryker is a MedTech compounder with 11% organic revenue growth and expanding margins, driven by technology leadership and a razor/razorblade model. SYK's wide economic moat is underpinned by high switching costs, clinical evidence, patents, and scale advantages in logistics. I value SYK at $336.24 per share, near its current price of $341, offering no margin of safety; recommend holding for current shareholders. Prospective investors should watch for a 15% discount to fair value, with an attractive entry at $289 per share. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Recovery Prospects
Stryker's fair value estimate has been adjusted slightly lower to $386.80 from $389.24 as analysts temper price targets in response to lower utilization expectations, inflation headwinds, and more conservative long term margin and P/E assumptions. Analyst Commentary Recent Street research on Stryker has been active, with most updates focused on resetting price targets and reassessing long term assumptions around utilization, inflation, and margins.Anlatı Güncellemesi • May 31
SYK: Hospital Digitization And Cyber Resilience Will Drive 2026 Rebound Potential
Analysts have trimmed Stryker's updated price target slightly, reflecting a minor change of about $0.11 and combining a series of recent target cuts from multiple firms with one modest increase, as they reassess assumptions around discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts who recently raised or affirmed higher targets highlight what they see as healthy fundamentals in U.S. medical technology, which they argue can support Stryker's growth assumptions that underpin current P/E expectations.Anlatı Güncellemesi • May 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Upside
Analysts have nudged Stryker's fair value estimate lower to about $389 from roughly $419, as a wave of reduced price targets led by firms like Truist, Barclays and others has been paired with updated assumptions for slightly lower future P/E multiples, alongside higher projected revenue growth and profit margins. Analyst Commentary Recent research around Stryker has tilted more cautious, with a cluster of reduced price targets across multiple firms, offset by a smaller group of more supportive views.Analiz Makalesi • May 04
Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...Anlatı Güncellemesi • Apr 21
SYK: Diversified Portfolio And Hospital Digitization Will Support 2026 Upside
Analysts have trimmed Stryker's fair value estimate by about $6 to $419, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and a slightly lower future P/E multiple, even as profit margin expectations are marginally higher. Analyst Commentary Recent Street research on Stryker shows a mix of optimism about the company’s long term growth drivers and caution around near term valuation and risk.Anlatı Güncellemesi • Apr 06
SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside
The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.Anlatı Güncellemesi • Mar 22
SYK: Diversified Portfolio And Robotics Adoption Will Support 2026 Upside
Analysts have trimmed the Stryker fair value estimate by less than $1 to about $424 per share, reflecting a slightly higher discount rate and a modestly lower assumed future P/E multiple. Recent research cites mixed price target moves and differing views on near term catalysts and sector trends.Anlatı Güncellemesi • Mar 07
SYK: Diversified Product Reach And Robotics Expansion Will Support 2026 Upside
The analyst fair value estimate for Stryker has edged up by about $0.50 to $424.90, as analysts factor in recent price target moves, including several Outperform ratings that highlight the company's broader product reach and diversified growth profile. Analyst Commentary Recent research on Stryker reflects a mix of optimism about the company’s growth profile and some caution on valuation and sector level risks.Anlatı Güncellemesi • Feb 20
SYK: Diversified Medtech Portfolio And Robotics Execution Will Support 2026 Upside
Analysts made a modest trim to their blended Stryker price target, reflecting mixed recent revisions that range from higher targets up to $465 with Outperform ratings to lower targets near $390 and $399 with a Hold rating, as they weigh the company's broader product reach and expected sales and earnings trends against valuation and sector-level risks. Analyst Commentary Recent research on Stryker reflects a split view, with some analysts leaning into the growth story and others more guarded on valuation and sector risks.Analiz Makalesi • Feb 09
Stryker's (NYSE:SYK) Earnings Seem To Be Promising
Stryker Corporation's ( NYSE:SYK ) recent earnings report didn't offer any surprises, with the shares unchanged over...Analiz Makalesi • Feb 07
Stryker (NYSE:SYK) Is Due To Pay A Dividend Of $0.88
Stryker Corporation ( NYSE:SYK ) will pay a dividend of $0.88 on the 30th of April. This takes the annual payment to...Anlatı Güncellemesi • Feb 06
SYK: Orthopedics And Robotics Execution Will Support 2026 Rebound In Medtech Sentiment
Analysts have reduced their fair value estimate for Stryker by about $3 to $424, reflecting slightly softer revenue growth assumptions, a future P/E multiple closer to 34, and a modestly higher profit margin outlook following recent mixed price target changes across Wall Street. Analyst Commentary Recent research coverage on Stryker reflects a mix of optimism and caution, with several firms adjusting price targets and ratings in different directions.Anlatı Güncellemesi • Jan 22
SYK: Orthopedics And Robotics Execution Will Support 2026 Upside Potential
Analysts have inched their average price target on Stryker higher, with a modest fair value lift to about US$427.40, as they weigh mixed target changes across firms against ongoing views that the company remains a high quality large-cap MedTech name heading into 2026. Analyst Commentary Recent Street research on Stryker shows a split tape, with several firms lifting targets and ratings while others trim fair values or stay neutral.Anlatı Güncellemesi • Jan 08
SYK: Orthopedics Strength And Robotics Adoption Will Support Long-Term Upside
Narrative Update: Stryker The analyst price target for Stryker has been adjusted slightly lower to reflect a fair value estimate of about $427.22. Analysts point to mixed but generally solid recent research that highlights compressed forward multiples, updated targets in the $390 to $453 range, and ongoing views of Stryker as a high quality large cap MedTech name, with attractive entry points and healthy procedure and CapEx trends into 2026.Anlatı Güncellemesi • Dec 19
SYK: Expanding Orthopedics And Robotics Footprint Will Drive Long-Term Upside Potential
Analysts have modestly trimmed our fair value estimate for Stryker to approximately $428 from about $433 per share, reflecting a slightly higher discount rate and lower valuation multiple, even as they acknowledge improving revenue growth, rising profit margins, and continued operating leverage highlighted in recent research updates and investor day commentary. Analyst Commentary Street research on Stryker has been active in recent weeks, with modestly higher and lower price targets reflecting a balanced mix of optimism on execution and caution on MedTech sentiment and relative growth.Analiz Makalesi • Dec 14
Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88
Stryker Corporation's ( NYSE:SYK ) periodic dividend will be increasing on the 30th of January to $0.88, with investors...Analiz Makalesi • Sep 08
Does Stryker (NYSE:SYK) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Hissedar Getirileri
| SYK | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -0.7% | 1.5% | -1.2% |
| 1Y | -15.7% | -11.6% | 18.3% |
Getiri vs. Endüstri: SYK geçen yıl % -11.6 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: SYK geçen yıl % 18.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| SYK volatility | |
|---|---|
| SYK Average Weekly Movement | 5.4% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: SYK son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: SYK 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1941 | 56,000 | Kevin Lobo | www.stryker.com |
Stryker Corporation, Amerika Birleşik Devletleri'nde ve uluslararası alanda bir tıbbi teknoloji şirketi olarak faaliyet göstermektedir. MedSurg ve Nöroteknoloji ve Ortopedi olmak üzere iki segmentte faaliyet göstermektedir. MedSurg ve Nöroteknoloji segmenti, cerrahi ekipman, hasta ve hasta bakıcı güvenliği teknolojileri, navigasyon sistemleri, endoskopik ve iletişim sistemleri, hasta taşıma, acil tıbbi ekipman ve tek kullanımlık yoğun bakım ürünleri, klinik iletişim ve yapay zeka destekli sanal bakım platformu teknolojisi ve akut iskemik ve hemorajik inme ve venöz tromboembolizm tedavisi için minimal invaziv ürünler; geleneksel beyin ve açık kafatası bazlı cerrahi prosedür ürünleri; ve sentetik kemik greftleri ve vertebral büyütme ürünleri dahil olmak üzere ortobiyolojik ve biyocerrahi ürünleri sunmaktadır.
Stryker Corporation Temel Bilgiler Özeti
| SYK temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$126.37b |
| Kazançlar(TTM) | US$3.73b |
| Gelir(TTM) | US$25.84b |
33.9x
F/K Oranı4.9x
P/S OranıSYK aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| SYK gelir tablosu (TTM) | |
|---|---|
| Gelir | US$25.84b |
| Gelir Maliyeti | US$8.89b |
| Brüt Kâr | US$16.95b |
| Diğer Giderler | US$13.22b |
| Kazançlar | US$3.73b |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 9.72 |
| Brüt Marj | 65.59% |
| Net Kâr Marjı | 14.43% |
| Borç/Özkaynak Oranı | 62.3% |
SYK uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
1.1%
Mevcut Temettü Verimi36%
Ödeme OranıSYK güvenilir bir temettü ödüyor mu?
SYK temettü geçmişine ve kıyaslamalara bakın| Stryker temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Sep 30 2026 |
| Temettü Ödeme Tarihi | Oct 30 2026 |
| Eski temettüye kadar geçen günler | 37 days |
| Temettü ödeme tarihine kadar geçen günler | 67 days |
SYK güvenilir bir temettü ödüyor mu?
SYK temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/24 04:00 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Stryker Corporation 54 Bu analistlerden 27, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Adam Feinstein | Barclays |